Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.Board of Regents, University of Texas Syste

Pengaruh Pembelajaran Problem Based Learning (PBL) Terhadap Kemampuan Representasi Matematis Siswa Di Kelas VIII Yayasan Perguruan Islam SMP Cerdasmurni Tembung

Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.U

Evaluation of alpha-1-proteinase inhibitor in the diagnosis of protein-losing enteropathy in dogs

Vita.Canine alpha-l-proteinase (α[1]-PI) inhibitor is a member of the serpin family with a molecular weight of 56,000 daltons. Although the trypsin inhibitory capacities of this protein were described first (thus the alternate name, alpha-1-antitrypsin), it may also inhibit elastase, chymotrypsin, plasmin, kallikrein, and thrombin. Interest in a,-PI first occurred when deficiency of this protease inhibitor was associated with clinical disease in humans. A number of other diseases including neonatal liver disease, adult onset liver disease, and panniculitis have also been associated with a deficiency of this proteinase inhibitor. Although α[1]-PI concentrations have been measured in many animal species, little effort has been directed towards identifying associated clinical syndromes in species other than man. One component of the study reported here was development of a microtiter assay for determination of the presence of trypsin or trypsin-like activity, or trypsin inhibitors, in purification products. Advantages of this assay over many others described in the literature is that it requires only small volumes of unknowns and multiple samples can be assayed quickly and efficiently. Canine PI was purified by a modification of the technique described by Abrams. The purification process involved ammonium sulfate fractionation, gel filtration, ion-exchange chromatography, and affinity chromatography (Concanavalin A-Sepharose column). Antiserum raised against the purified canine α[1]-PI showed immunologic cross-reactivity with human and bovine α[1]-PI. Immunoblotting was investigated as a method of quantitating α[1]-PI for the diagnosis of protein losing enteropathy in dogs. Although α[1]-PI could be detected in the feces of dogs by this method, the specific antibody used recognized other proteins in feces which might be breakdown products of α[1]-PI or albumin, or proteins with common epitopes. Additionally, extraction of α[1]-PI from feces appeared to be highly variable among the samples studied and quantitation of protein content between blots was inconsistent. Given these facts, determination of fecal α[1]-PI in dogs does not presently appear to be a clinically useful tool

Evaluation of alpha-1-proteinase inhibitor in the diagnosis of protein-losing enteropathy in dogs

Vita.Canine alpha-l-proteinase (α[1]-PI) inhibitor is a member of the serpin family with a molecular weight of 56,000 daltons. Although the trypsin inhibitory capacities of this protein were described first (thus the alternate name, alpha-1-antitrypsin), it may also inhibit elastase, chymotrypsin, plasmin, kallikrein, and thrombin. Interest in a,-PI first occurred when deficiency of this protease inhibitor was associated with clinical disease in humans. A number of other diseases including neonatal liver disease, adult onset liver disease, and panniculitis have also been associated with a deficiency of this proteinase inhibitor. Although α[1]-PI concentrations have been measured in many animal species, little effort has been directed towards identifying associated clinical syndromes in species other than man. One component of the study reported here was development of a microtiter assay for determination of the presence of trypsin or trypsin-like activity, or trypsin inhibitors, in purification products. Advantages of this assay over many others described in the literature is that it requires only small volumes of unknowns and multiple samples can be assayed quickly and efficiently. Canine PI was purified by a modification of the technique described by Abrams. The purification process involved ammonium sulfate fractionation, gel filtration, ion-exchange chromatography, and affinity chromatography (Concanavalin A-Sepharose column). Antiserum raised against the purified canine α[1]-PI showed immunologic cross-reactivity with human and bovine α[1]-PI. Immunoblotting was investigated as a method of quantitating α[1]-PI for the diagnosis of protein losing enteropathy in dogs. Although α[1]-PI could be detected in the feces of dogs by this method, the specific antibody used recognized other proteins in feces which might be breakdown products of α[1]-PI or albumin, or proteins with common epitopes. Additionally, extraction of α[1]-PI from feces appeared to be highly variable among the samples studied and quantitation of protein content between blots was inconsistent. Given these facts, determination of fecal α[1]-PI in dogs does not presently appear to be a clinically useful tool

Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.U

Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.U

Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.U

Compositions and methods for drug sensitization of parasites

Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.U

Esophageal hiatal hernia in three exotic felines--Lynx lynx, Puma concolore, Panthera leo.

Hiatal hernia was diagnosed in three exotic felines-lynx (Lynx lynx), cougar (Puma concolore), and lion (Panthera leo). All cats had a history of anorexia. Thoracic and abdominal radiographs showed evidence of a soft tissue mass within the caudal mediastinum suggestive of a hiatal hernia in all animals. A barium esophagram was performed in one case. All animals underwent thoracic or abdominal surgery for hernia reduction. Surgical procedures included: intercostal thoracotomy with herniorrhaphy and esophagopexy (lynx and cougar), and incisional gastropexy (lion). Concurrent surgical procedures performed were gastrotomy for gastric foreign body removal and jejunostomy tube placement. Clinical signs related to the hiatal hernia disappeared after surgery and recurrence of signs was not reported for the time of follow-up